2022
DOI: 10.3390/jcm11144080
|View full text |Cite
|
Sign up to set email alerts
|

Dyslipidemia in Transplant Patients: Which Therapy?

Abstract: Cardiovascular disease is the most important cause of death worldwide in recent years; an increasing trend is also shown in organ transplant patients subjected to immunosuppressive therapies, in which cardiovascular diseases represent one of the most frequent causes of long-term mortality. This is also linked to immunosuppressant-induced dyslipidemia, which occurs in 27 to 71% of organ transplant recipients. The aim of this review is to clarify the pathophysiological mechanisms underlying dyslipidemia in patie… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
5
1

Relationship

1
5

Authors

Journals

citations
Cited by 7 publications
(3 citation statements)
references
References 152 publications
(191 reference statements)
0
3
0
Order By: Relevance
“…Despite optimal therapy for dyslipidaemia, many patients (up to 50%) with hyperlipidaemia after mTOR inhibitors therapy do not achieve the cholesterol and triglyceride concentrations recommended by the most prestigious scientific societies. However, the treatment of transplant patients with drug-induced dyslipidaemia was addressed in a recent review [ 81 ]. The other side of the coin is the protective role played by some mTOR inhibitors against atherosclerosis and thrombosis.…”
Section: Mammalian Target Of Rapamycin Inhibitorsmentioning
confidence: 99%
“…Despite optimal therapy for dyslipidaemia, many patients (up to 50%) with hyperlipidaemia after mTOR inhibitors therapy do not achieve the cholesterol and triglyceride concentrations recommended by the most prestigious scientific societies. However, the treatment of transplant patients with drug-induced dyslipidaemia was addressed in a recent review [ 81 ]. The other side of the coin is the protective role played by some mTOR inhibitors against atherosclerosis and thrombosis.…”
Section: Mammalian Target Of Rapamycin Inhibitorsmentioning
confidence: 99%
“…Data from [8,9,14 ▪ ,15,16,25,26]. ACC, acetyl-coenzyme A carboxylase; HMG-CoA, 3-hydroxy-3-methylglutaryl-coenzyme; LDL, low-density lipoprotein; MAPK, mitogen-activated protein kinase.…”
Section: Effect Of Immunosuppressive Drugs On Dyslipidemiamentioning
confidence: 99%
“…The mechanism of CNI-induced dyslipidemia is somewhat similar to the corticosteroid. CNIs increase FFA formation by enhancing hepatic lipoprotein synthesis in combination with diminishing LPL activity for clearance of circulating triglycerides, particularly from VLDL [14 ▪ ]. The effect on hypercholesterolemia is mediated through lowering bile acid formation and inhibiting mitochondrial 27-hydroxylase (CYP27A1), but the activity of HMG-CoA reductase sustainably increases [15].…”
Section: Effect Of Immunosuppressive Drugs On Dyslipidemiamentioning
confidence: 99%